

Accepted Article

**Absence of severe complications from SARS-CoV-2 infection in children with
rheumatic diseases treated with biologic drugs**

Giovanni Filocamo¹, Francesca Minoia¹, Simone Carbogno¹, Stefania Costi², Micol Romano², Rolando Cimaz²⁻³, for the Pediatric Rheumatology Group of the Milan Area

1. Fondazione IRCCS Cà Granda ospedale Maggiore Policlinico, Milan, Italy

2. ASST G.Pini-CTO, Milan, Italy

3. Department of Clinical Sciences and Community Health, and RECAP-RD, University of Milan, Italy

Corresponding Author:

Giovanni Filocamo, M.D. PhD

Pediatric Rheumatology, Pediatric Medium Intensity Care Unit

Fondazione IRCCS Cà Granda, Ospedale Maggiore Policlinico

Clinica De Marchi

Via della Commenda, 9

20122 Milano

Email: giovanni.filocamo@policlinico.mi.it

This article has been accepted for publication in The Journal of Rheumatology following full peer review. This version has not gone through proper copyediting, proofreading and typesetting, and therefore will not be identical to the final published version. Reprints and permissions are not available for this version. Please cite this article as doi: 10.3899/jrheum.200483. This accepted article is protected by copyright. All rights reserved.

To the Editor

We read with interest the Editorial by Cron and Chatam (1) suggesting a cytokine storm syndrome (CSS) occurring in response to SARS-CoV-2 infection and, consequently, a possible role for targeted approaches to blocking inflammatory cytokines.

Almost 30% of COVID-19 patients develops severe acute respiratory distress syndrome (ARDS) with high mortality rate. (2) In those critically ill patients, there are both clinical signs and symptoms, as well as laboratory abnormalities, that suggest a CSS is occurring in response to the viral infection. (1)

In contrast with adults, pediatric patients with COVID-19 seem to have a milder clinical course and asymptomatic SARS-CoV-2 infections may be frequent. (3) However, albeit rarely, severe infections may occur even in children, with PICU admission or high-flow ventilation. In a recent Spanish cohort, 60% of confirmed infections in children required hospitalization. (4)

COVID-19 pediatric transmission routes include close contact with family members, exposure to epidemic areas, or both . The school community is a place that can rapidly enhance the spread of a highly infectious virus, and Italian children may have been exposed to SARS-CoV-2 infection weeks before the school lockdown decided by the government.

Several concerns have been raised about children with autoimmune or autoinflammatory conditions characterized by an increased infectious risk, due both to the immune dysregulation of the underlying disease or to its immunosuppressive treatment, including glucocorticoids (GCs), conventional disease-modifying antirheumatic drugs (cDMARDs) and biologic disease-modifying drugs (bDMARDs). However, the increasing knowledge about the pathophysiology of SARS-CoV-2 infection is paradoxically supporting the beneficial role of some well-known anti-rheumatic drugs for the management of severe COVID-19. (5) Preliminary experience has shown that adult patients with chronic arthritis treated with bDMARDs or cDMARDs do not seem to be at increased risk of respiratory or life-threatening complications from SARS-CoV-2 compared with the general population. (6) Moreover, in another recent report on patients with Inflammatory Bowel Disease

Downloaded on April 18, 2024 from www.jrheum.org

(IBD) treated with cDMARDS and or bDMARDS none of them was affected by a complicated SARS-CoV-2 related pneumonia. (7)

Pediatric rheumatologists are certainly involved in decisions related to chronic care and management during this difficult period, (8), but to the best of our knowledge there are no published data yet related to the risk of severe complications from SARS-CoV-2 infection in children affected with rheumatic diseases .

In order to investigate the impact of COVID-19 on pediatric patients with rheumatic diseases treated with bDMARDS, with or without cDMARDS, a questionnaire was prepared and administered in our pediatric rheumatology clinics in Milan, Lombardy, the most affected region in Italy. The survey evaluated patients' health conditions, direct exposure to subjects known to be affected by COVID-19, modifications of ongoing DMARDS treatment and potential flares of underlying disease during the early weeks of Italian COVID-19 outbreak. All patients had provided their informed consent for the use of personal and clinical data for scientific purposes, and no patient refused to participate.

Between 25th February and 14th April 2020, we collected data from children treated with bDMARDS and followed in the ASST Pini and Fondazione IRCCS Ca' Granda Policlinico hospitals in Milan. The survey was administered face-to-face to all patients during outpatient clinic visits, or by telephone in those who missed a scheduled visit during the period under review. The final study population included 123 pediatric patients (83F, 62 %, median age 13 years, range 4-20) on bDMARDS for chronic rheumatic diseases (89 with juvenile idiopathic arthritis, 5 with chronic uveitis, 5 with autoinflammatory disease, 24 with others chronic rheumatic diseases). As shown in **Table 1**, none of them were confirmed cases of COVID-19. Eight children presented mild respiratory symptoms, three of them were family members of adults suspected for COVID-19 infection. In our region diagnostic swabs are not routinely performed, and a case is considered probable in the context of epidemic area and compatible clinical signs and symptoms (fever, cough, dyspnea). No patient stopped ongoing therapy or needed hospitalization. All contacted patients

declared that they had adopted a preventive strategy against COVID-19 based on social distancing and use of personal protective equipment, even if this usually happened only after the beginning of the outbreak.

Our results do not allow any conclusions on the incidence rate of SARS-CoV-2 infection in children with rheumatic diseases, nor on the overall outcome of immunocompromised patients affected by COVID-19. However, according to the above mentioned observations on adult rheumatology patients (6), our preliminary experience supports the idea that patients with chronic diseases treated with bDMARDs do not seem to be at increased risk of respiratory or life-threatening complications from SARS-CoV-2 compared with the general population. Keeping the disease under control may therefore be extremely important even during the epidemic, since it is known that disease activity may be a risk factor for superimposed infections.

Table 1.

Disease	
Juvenile Idiopathic Arthritis (JIA)	89 (72.3)
<i>Oligoarticular</i>	60 (48.8)
<i>Poliarticular (Rheumatoid Factor negative)</i>	14 (11.4)
<i>Poliarticular (Rheumatoid Factor positive)</i>	0
<i>Enthesitis Related Arthritis</i>	4 (3.3)
<i>Systemic JIA</i>	7 (5.7)
<i>Psoriatic</i>	4 (3.3)
Autoinflammatory diseases	5 (4.1)
Cronic uveitis	5 (4.1)
Recurrent pericarditis	2 (1.6)
Others	22 (17.9)
Female	83 (62.4)
Median disease duration *	6 (3-10)
bDMARDS	
Anti TNF	95 (77.2)
<i>Etanercept</i>	38 (30.9)
<i>Adalimumab</i>	53 (43.1)
<i>Infliximab</i>	4 (3.3)
Anakinra	7 (5.7)
Tocilizumab	7 (7.7)
Canakinumab	2 (1.6)
Baricitinib	1 (0.8)
Other	11 (8.9)
Concomitant cDMARDS	
Methotrexate	77 (62.7)
Colchicine	3 (2.4)
Cyclosporine	1 (0.8)
Mycophenolate mofetil	1 (0.8)
Systemic steroids	6 (4.9)
Confirmed COVID – 19 infection	0
Suspected COVID – 19 infection	0
Children with mild respiratory symptoms	8 (3 of them family members of adults suspected for COVID-19)

Principal characteristics of 123 pediatric patients with chronic rheumatic diseases on bDMARDS. Values are expressed in numbers (%). * median (1°-3° quartile)

Downloaded on April 18, 2024 from www.jrheum.org

References

1. Cron RQ, Chatham WW. The Rheumatologist's Role in Covid-19. *J Rheumatol*. 2020 Mar 24. pii: jrheum.200334. doi: 10.3899/jrheum.200334.
2. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y, Zhao Y, Li Y, Wang X, Peng Z. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. *JAMA*. 2020 Feb 7. doi: 10.1001/jama.2020.1585.
3. Lu X, Zhang L, Du H, Zhang J, Li YY, Qu J, Zhang W, Wang Y, Bao S, Li Y, Wu C, Liu H, Liu D, Shao J, Peng X, Yang Y, Liu Z, Xiang Y, Zhang F, Silva RM, Pinkerton KE, Shen K, Xiao H, Xu S, Wong GWK; Chinese Pediatric Novel Coronavirus Study Team. SARS-CoV-2 Infection in Children. *N Engl J Med*. 2020 Mar 18. doi: 10.1056/NEJMc2005073.
4. Tagarro A, Epalza C, Santos M, Sanz-Santaefemia FJ, Otheo E, Moraleda C, Calvo C. Screening and Severity of Coronavirus Disease 2019 (COVID-19) in Children in Madrid, Spain. *JAMA Pediatr*. 2020 Apr 8. doi: 10.1001/jamapediatrics.2020.1346.
5. Favalli EG, Ingegnoli F, De Lucia O, Cincinelli G, Cimaz R, Caporali R. COVID-19 infection and rheumatoid arthritis: Faraway, so close! *Autoimmun Rev*. 2020 Mar 20:102523. doi: 10.1016/j.autrev.2020.102523.
6. Monti S, Balduzzi S, Delvino P, Bellis E, Quadrelli VS, Montecucco C. Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies. *Ann Rheum Dis*. 2020 Apr 2. pii: annrheumdis-2020-217424. doi: 10.1136/annrheumdis-2020-217424.
7. Norsa L, Indriolo A, Sansotta N, Cosimo P, Greco S, D'Antiga L. Uneventful course in IBD patients during SARS-CoV-2 outbreak in northern Italy. *Gastroenterology*. 2020 Apr 2. pii: S0016-5085(20)30445-5. doi: 10.1053/j.gastro.2020.03.062.

8. Licciardi F, Giani T, Baldini L, Favalli E, Caporali R, Cimaz R. COVID-19 and what pediatric rheumatologists should know. A review from a highly affected country. *Pediatr Rheumatol Online J.* article in press